jama tirzepatide Ophthalmic Complications Observed After Use of GLP-1 Agonists Semaglutide and #tirzepatide have improved

According to FDA prescribing information, these effects vary by product and dose: For Ozempic (diabetes treatment): Nausea (15-20% of patients) Diarrhea (8-9% of patients) Vomiting (5-9% of patients) Constipation (3-7% of patients) Abdominal pain (5-6% of patients) For Wegovy (weight management), gastrointestinal effects are more common at the higher therapeutic dose: Nausea (up to 44% of patients) Diarrhea (up to 30% of patients) Vomiting (up to 24% of patients) Constipation (up to 24% of patients) Abdominal pain (up to 20% of patients) These effects are generally mild to moderate and tend to diminish with continued use

Therefore, individuals on both thyroid medication and GLP-1s need their thyroid hormone levels monitored more frequently, as their dosage may need to be adjusted downward over time to avoid overtreatment

That greater average loss is tied to its dual mechanism, though individual responses vary with lifestyle changes and personal health factors

In diabetes, HFpEF is predominantly driven by coronary microvascular disease/dysfunction, systemic inflammation, as well as cardiovascular autonomic dysfunction (which is very specific to diabetes) and a deficient heart oxidative metabolism, all leading to remodeling of the heart and increased stiffness, while HFrEF is predominantly driven by adverse remodeling secondary to accelerated atherosclerotic CVD (ASCVD)